Drugs / YH4808
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02072447 | Mar → Apr 2014 | gastroesophageal reflux disease | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT02176668 | Jun → Nov 2014 | — | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01921647 | Jul → Nov 2013 | — | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01876615 | Jul → Oct 2013 | — | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01825707 | Jan → Mar 2013 | — | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01761513 | Nov 2012 → Feb 2013 | — | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01520012 | Feb → May 2012 | — | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01007019 | Nov 2009 → Mar 2011 | — | Yuhan Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01538849 | Dec 2012 → Nov 2013 | peptic esophagitis | Yuhan Corporation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YH4808 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01520012 ↗ |
| Action | Inhibit | “inhibitory effects against gastric acid secretion” PMID 33062627 ↗ Sep 2020 |
| Modality | Other / unclassified | “novel potassium-competitive acid blocker” PMID 34621707 ↗ Sep 2021 |
| Route | Oral | “After Oral Administration” NCT01007019 ↗ |